Dublin, April 30, 2024 (GLOBE NEWSWIRE) -- The "Alpha-1 Antitrypsin Deficiency - Epidemiology Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
This 'Alpha-1 Antitrypsin Deficiency (AATD) - Epidemiology Forecast - 2032' report delivers an in-depth understanding of alpha-1 antitrypsin deficiency, historical and forecasted epidemiology, as well as the trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Alpha-1 Antitrypsin Deficiency Epidemiology Perspective
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases of alpha-1 antitrypsin deficiency, genotype-specific prevalent cases of alpha-1 antitrypsin deficiency, and comorbidity-associated prevalent cases of alpha-1 antitrypsin deficiency in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2019 to 2032.
Alpha-1 Antitrypsin Deficiency Detailed Epidemiology Segmentation
- In 2022, there were approximately 220,352 prevalent cases of alpha-1 antitrypsin deficiency in the 7MM. The US accounted for nearly 60% of the total prevalent cases of alpha-1 antitrypsin deficiency in the 7MM, and these cases are expected to increase during the forecast period.
- As per The epidemiology model, the genotype of alpha-1 antitrypsin deficiency was divided into three groups: PiZZ, PiSZ, and others (including PiMZ and other less common genotypes). In 2022, there were approximately 119,274, 7,316, and 5,937 cases of PiZZ, PiSZ, and other genotypes, respectively. The genotype-specific prevalent cases of alpha-1 antitrypsin deficiency are projected to increase by 2032.
- In 2022, in the US, comorbidity associated with lung diseases was most common, occurring in around 77% of the total alpha-1 antitrypsin deficiency cases, followed by other diseases occurring in around 15% of the cases, while 8% of the cases had liver diseases. The report estimates that by 2032, these cases are expected to increase.
- Among EU4 and the UK, the UK accounted for the highest diagnosed prevalent cases of alpha-1 antitrypsin deficiency, around 22,597 cases, while Italy had the least cases of alpha-1 antitrypsin deficiency, nearly 12,219 in 2022.
- In EU4 and the UK, of the total prevalent cases of alpha-1 antitrypsin deficiency, around 78% were PiZZ genotypes, 10% were PiSZ, and nearly 12% were of other genotypes in 2022. These cases are expected to rise during the forecast period (2023-2032).
- In EU4 and the UK, comorbidities associated with lung diseases were ranked first with 70,546 cases, followed by other diseases with 8,939 cases, and liver disease with 8,316 cases in 2022.
- In 2022, Japan accounted for the lowest prevalent cases of alpha-1 antitrypsin deficiency among the 7MM, making up nearly 0.01% of the total cases. The cases are estimated to change during the forecast period.
- In Japan, lung disease-associated comorbidities in alpha-1 antitrypsin deficiency occurred in around 18 cases, while liver diseases and other diseases were found in nearly two and three cases of alpha-1 antitrypsin deficiency, respectively, in 2022.
Scope of the Report
- The report covers a descriptive overview of alpha-1 antitrypsin deficiency, explaining its symptoms, pathophysiology, and various diagnostic approaches.
- The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
- The report assesses the disease risk and burden of alpha-1 antitrypsin deficiency.
- The report helps recognize the growth opportunities in the 7MM concerning the patient population.
- The report provides the segmentation of the disease epidemiology for the 7MM, the total prevalent cases of alpha-1 antitrypsin deficiency, genotype-specific prevalent cases of alpha-1 antitrypsin deficiency, and comorbidity-associated prevalent cases of alpha-1 antitrypsin deficiency.
Report Highlights
- Ten Years Forecast of Alpha-1 Antitrypsin Deficiency
- The 7MM Coverage
- Total Prevalent Cases of Alpha-1 Antitrypsin Deficiency
- Gender-specific Prevalent Cases of Alpha-1 Antitrypsin Deficiency
- Comorbidity-associated Prevalent Cases of Alpha-1 Antitrypsin Deficiency
Reasons to Buy
- Develop business strategies by understanding the trends shaping and driving the 7MM alpha-1 antitrypsin deficiency epidemiology forecast.
- The alpha-1 antitrypsin deficiency epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
- The alpha-1 antitrypsin deficiency epidemiology model developed by the publisher is easy to navigate, interactive with a dashboard, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.
Key Assessments
- Patient Segmentation
- Disease Risk and Burden
- Risk of Disease by Segmentation
- Factors Driving Growth in a Specific Patient Population
Geographies Covered
- The United States
- EU4 (Germany, France, Italy, and Spain) and the United Kingdom
- Japan
Study Period: 2019-2032
Key Topics Covered:
1. Key Insights
2. Report Introduction
3. Alpha-1 Antitrypsin Deficiency Epidemiology Overview at a Glance
3.1. Patient Share (%) Distribution of Alpha-1 Antitrypsin Deficiency in 2019
3.2. Patient Share (%) Distribution of Alpha-1 Antitrypsin Deficiency in 2032
4. Methodology of Alpha-1 Antitrypsin Deficiency Epidemiology
5. Executive Summary of Alpha-1 Antitrypsin Deficiency
6. Disease Background and Overview
6.1. Introduction to Alpha-1 Antitrypsin Deficiency
6.2. Clinical Manifestations
6.3. Etiology
6.4. Risk Factors
6.5. Pathogenesis
6.6. Diagnosis
6.6.1. Biomarkers
6.6.2. Differential Diagnosis
7. Patient Journey
8. Epidemiology and Patient Population
8.1. Key Findings
8.2. Assumptions and Rationale
8.2.1. Total Prevalent Cases of Alpha-1 Antitrypsin Deficiency
8.2.2. Genotype-specific Prevalent Cases of Alpha-1 Antitrypsin Deficiency
8.2.3. Comorbidity-associated Prevalent Cases of Alpha-1 Antitrypsin Deficiency
8.3. Total Prevalent Cases of Alpha-1 Antitrypsin Deficiency in the 7MM
8.4. The US
8.4.1. Total Prevalent Cases of Alpha-1 Antitrypsin Deficiency in the US
8.4.2. Genotype-specific Prevalent Cases of Alpha-1 Antitrypsin Deficiency in the US
8.4.3. Comorbidity-associated Prevalent Cases of Alpha-1 Antitrypsin Deficiency in the US
8.5. EU4 and the UK
8.5.1. Total Prevalent Cases of Alpha-1 Antitrypsin Deficiency in EU4 and the UK
8.5.2. Genotype-specific Prevalent Cases of Alpha-1 Antitrypsin Deficiency in EU4 and the UK
8.5.3. Comorbidity-associated Prevalent Cases of Alpha-1 Antitrypsin Deficiency in EU4 and the UK
8.6. Japan
8.6.1. Total Prevalent Cases of Alpha-1 Antitrypsin Deficiency in Japan
8.6.2. Genotype-specific Prevalent Cases of Alpha-1 Antitrypsin Deficiency in Japan
8.6.3. Comorbidity-associated Prevalent Cases of Alpha-1 Antitrypsin Deficiency in Japan
9. KOL Views
10. Unmet Needs
11. Appendix
For more information about this report visit https://www.researchandmarkets.com/r/y7g39i
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
